Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.
Drew Rasco(Texas Oncology), Yifan Zhai(Unknown), Zhiyan Liang(East China University of Science and Technology), Yuefen Tang, Alex Amaya(South Texas Accelerated Research Therapeutics), Dajun Yang(Ascendis Pharma (Denmark)), Jason Chen(Brigham and Women's Hospital), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Jiao Ji(Sun Yat-sen University), Hengbang Wang
Cited by 6
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response
|The Journal of Immunology|2000|402